Firefly Neuroscience, Inc. AIFF
2.01
0.82
68.91%
as of 25 Sep
- Market cap
- $18.7M
- P/E
- 0.0×
Follow AIFF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(411.76%) | (675.60%) | (136.27%) | (70.52%) | |
| (288.94%) | (325.39%) | (79.79%) | (59.52%) | ||
ROIC |
(114.77%) | (113.19%) | (103.49%) | (105.08%) | |
Return on Tangible Assets |
(868.87%) | (1,811.74%) | (421.28%) | (112.91%) | |
Average Days of Receivables |
85.77 | 62.01 | 44.47 | 38.14 | |
Free Cash Flow per Share |
(0.59) | (0.67) | (0.48) | (0.35) | |
Free Cash Flow |
(7.93) | (8.32) | (7.81) | (7.20) | |
Capital Expenditures |
(0.32) | (0.13) | (0.18) | (0.21) | |
Piotroski F-Score |
3.00 | 3.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(54.41%) | (78.91%) | (65.96%) | (29.26%) | |
Accounts Receivable Turnover |
1.61 | 8.16 | 10.09 | 12.49 | |
Accounts Payable Turnover |
1.98 | 1.09 | 0.52 | 0.84 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 11.27 | |
Average Days of Payables |
181.56 | 286.20 | 637.43 | 322.53 | |
Days of Inventory on Hand |
10.80 | 22.95 | 49.40 | 16.11 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
186.85% | 129.77% | 100.63% | 99.11% | |
Selling, General and Administrative Expense of Revenue |
998.47% | 680.21% | 491.10% | 439.63% | |
Share Based Compensation of Revenue |
94.51% | 118.21% | 100.25% | 89.22% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.30 | 0.33 | 0.82 | 0.74 | |
Depreciation/Fixed assets |
5.13 | 2.90 | 2.28 | 1.97 | |
Capex/Depreciation |
(0.27) | (0.30) | (0.40) | (0.46) | |
Revenue per Share |
0.06 | 0.09 | 0.10 | 0.09 | |
Operating CF per Share |
(0.56) | (0.66) | (0.47) | (0.34) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.41 | 0.11 | 0.11 | 0.12 | |
Net Profit Margin |
(3,269.09%) | (2,148.07%) | (586.17%) | (524.51%) |
Columns are period end dates